UCART123v1.2
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Acute Myeloid Leukemia
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Trial Timeline
Jun 19, 2017 → Dec 1, 2025
NCT ID
NCT03190278About UCART123v1.2
UCART123v1.2 is a phase 1 stage product being developed by Cellectis for Relapsed/Refractory Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT03190278. Target conditions include Relapsed/Refractory Acute Myeloid Leukemia.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Acute Myeloid Leukemia were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03190278 | Phase 1 | Active |
Competing Products
20 competing products in Relapsed/Refractory Acute Myeloid Leukemia